PubMed=2823470; DOI=10.1016/0042-6822(87)90171-1
Tanaka J., Ogura T., Sato H., Hatano M.
Establishment and biological characterization of an in vitro human cytomegalovirus latency model.
Virology 161:62-72(1987)

PubMed=2516841; DOI=10.1111/j.1349-7006.1989.tb01645.x
Ishizaka Y., Itoh F., Tahira T., Ikeda I., Ogura T., Sugimura T., Nagao M.
Presence of aberrant transcripts of ret proto-oncogene in a human papillary thyroid carcinoma cell line.
Jpn. J. Cancer Res. 80:1149-1152(1989)

PubMed=2334411; DOI=10.1016/0006-291X(90)92335-W
Ishizaka Y., Ushijima T., Sugimura T., Nagao M.
cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line.
Biochem. Biophys. Res. Commun. 168:402-408(1990)

PubMed=7491517; DOI=10.1016/s0039-6060(05)80108-4
Jossart G.H., Greulich K.M., Siperstein A.E., Duh Q.-Y., Clark O.H., Weier H.-U.G.
Molecular and cytogenetic characterization of a t(1;10;21) translocation in the human papillary thyroid cancer cell line TPC-1 expressing the ret/H4 chimeric transcript.
Surgery 118:1018-1023(1995)

PubMed=11439348; DOI=10.1038/sj.onc.1204531
Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.J.
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.
Oncogene 20:3845-3856(2001)

PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

PubMed=15980887; DOI=10.1038/labinvest.3700306
Nakamura N., Carney J.A., Jin L., Kajita S., Pallares J., Zhang H.-Y., Qian X., Sebo T.J., Erickson L.A., Lloyd R.V.
RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.
Lab. Invest. 85:1065-1075(2005)

PubMed=16778181; DOI=10.1158/0008-5472.CAN-06-0171
Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A., Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G., Rugolo M., Romeo G.
Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.
Cancer Res. 66:6087-6096(2006)

PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)

PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026
van Staveren W.C.G., Solis D.W., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.
Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113-8120(2007)

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371.1-371.11(2008)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=22087789; DOI=10.1186/1755-8166-4-26
Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.
Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.
Mol. Cytogenet. 4:26.1-26.8(2011)

PubMed=23162534; DOI=10.3389/fendo.2012.00133
Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.
Thyroid cancer cell lines: an overview.
Front. Endocrinol. 3:133.1-133.9(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)